House Passes ACT for ALS Reauthorization, Pushing Senate for Action

The legislation, introduced by Representatives Ken Calvert and Mike Quigley, seeks to extend vital infrastructure for ALS research and experimental treatment access through 2031. Since its inception, the ACT for ALS framework has provided a lifeline for patients ineligible for traditional clinical trials, offering pathways to investigational therapies that are otherwise unavailable.

Sheri Strahl, president and CEO of the ALS Network, described the House vote as a major milestone for families navigating the disease. Without swift Senate approval, existing research programs and patient support structures face a potential wind-down, threatening to disrupt ongoing progress. The organization is now calling on the Senate to capitalize on the House's bipartisan momentum to ensure these programs remain functional beyond the upcoming September cutoff.